Back to top
more

Organigram Global Inc. (OGI)

(Delayed Data from NSDQ)

$1.38 USD

1.38
394,880

0.00 (0.00%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.39 +0.01 (0.72%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Envista (NVST) Q3 Earnings Match Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of -50% and 5.67%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide Inc. (HITI) delivered earnings and revenue surprises of -175% and 3.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will OrganiGram (OGI) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neogen (NEOG) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -13.33% and 1.35%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akerna Corp. (KERN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akerna Corp. (KERN) delivered earnings and revenue surprises of -14.29% and 22.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will OrganiGram (OGI) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

OrganiGram (OGI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of -75% and 3.22%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: OrganiGram (OGI) Q4 Earnings Expected to Decline

by Zacks Equity Research

OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Levi Strauss, OrganiGram Holdings, United Natural Foods, Sprouts Farmers Market and Performance Food Group highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Levi Strauss, OrganiGram Holdings, United Natural Foods, Sprouts Farmers Market and Performance Food Group highlighted as Zacks Bull and Bear of the Day

Madeleine Johnson headshot

Bear of the Day: OrganiGram Holdings (OGI)

by Madeleine Johnson

This cannabis stock is still being weighed down by the coronavirus pandemic.

Zacks Equity Research

OrganiGram (OGI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of -200.00% and -26.82%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

OrganiGram (OGI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Inside the Top-Performing ETFs of Q1

by Sweta Killa

Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.

Zacks Equity Research

OrganiGram (OGI) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

OrganiGram (OGI) closed at $4.40 in the latest trading session, marking a -0.9% move from the prior day.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Organigram Holdings (OGI) Stock?

by Zacks Equity Research

Investors need to pay close attention to Organigram Holdings (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

OrganiGram (OGI) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

OrganiGram (OGI) closed at $3.03 in the latest trading session, marking a -1.62% move from the prior day.

Zacks Equity Research

Is the Options Market Predicting a Spike in OrganiGram (OGI) Stock?

by Zacks Equity Research

Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

Cannabis Stocks Rise on Hopes of Federal Legalization in US

by Zacks Equity Research

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

Zacks Equity Research

Organigram Holdings Inc. (OGI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Organigram Holdings Inc. (OGI) delivered earnings and revenue surprises of -300.00% and -8.34%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will OrganiGram (OGI) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is the Options Market Predicting a Spike in OrganiGram (OGI) Stock?

by Zacks Equity Research

Investors need to pay close attention to OrganiGram (OGI) stock based on the movements in the options market lately.

Zacks Equity Research

OrganiGram (OGI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of 0.00% and 2.79%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?